Refractoriness to infused platelets becomes a major clinical problem for many patients with acute myeloid leukemia (AML). Inadequate post-transfusion platelet count increments can be due to a number of host-related factors such as: splenomegaly, severe infection with high fever, disseminated intravascular coagulation, drug-mediated antibodies and/or alloimmunization, and occasionally by administration of platelets damaged or activated during collection or storage. Lymphocytotoxic antibody directed against HLA-A or -B antigens is an excellent serologic marker for alloimmunization. In one large study, the presence of anti-HLA antibodies was correlated with a poor post-transfusion platelet increase in over 90% of such patients, whereas patients lacking antibodies had satisfactory increments after transfusion 85% of the time.
Refractoriness to infused platelets becomes a major clinical problem for many patients with acute myeloid leukemia (AML). Inadequate post-transfusion platelet count increments can be due to a number of host-related factors such as: splenomegaly, severe infection with high fever, disseminated intravascular coagulation, drug-mediated antibodies and/or alloimmunization, and occasionally by administration of platelets damaged or activated during collection or storage. Lymphocytotoxic antibody directed against HLA-A or -B antigens is an excellent serologic marker for alloimmunization. In one large study, the presence of anti-HLA antibodies was correlated with a poor post-transfusion platelet increase in over 90% of such patients, whereas patients lacking antibodies had satisfactory increments after transfusion 85% of the time. 1 Similar predictive information can be obtained using a variety of antiplatelet antibody tests. Post-transfusion counts obtained at the conclusion of transfusion, at a time that the patient must be seen by the physician or nurse to switch infusion bags, are identical to counts obtained 1 h later and it is therefore relatively simple to assess the results of every platelet transfusion to determine if the expected count increment was achieved. 2 The incidence of alloimmunization appears to be unrelated to the number of transfusions that patients receive. In a series of 114 newly diagnosed AML patients receiving 2-10+ transfusions of pooled non-leukocyte-depleted platelet concentrates (PC) from random donors, there was no relationship between the number of transfusions or donor exposures, and the development of new anti-HLA antibody. 3 At the end of induction therapy, 35-40% of patients had developed antibody. The majority had persistence of the antibody, but 20% had disappearance of antibody over time. After marrow recovery from the induction therapy, 60% of patients remained antibody-negative and, indeed, never developed antibody or refractoriness to platelet transfusion despite multiple subsequent red blood cell and platelet transfusions, suggesting that they had become immune tolerant to histocompatibility antigens. These patients continued to be easily supported with random donor transfusions and therefore measurement of lymphocytotoxic antibody at this time in a patient's treatment course is helpful in predicting and arranging for their future transfusion needs.
The traditional management of alloimmune-mediated platelet refractoriness is by HLA typing of donors and recipients. A significant fraction of HLA 'matched' transfusions do not produce satisfactory increments, however, while some 'mismatched' transfusions are successful, and a number of studies have evaluated subtleties of HLA serology to attempt to explain these discrepancies. As one example, there is a high degree of serologic cross-reactivity amongst many of the HLA antigens and it was shown that one could mismatch for these similar antigens thereby increasing the number of donors available. 4 Other antigens, such as HLA B44 and 45, have weak expression on platelets such that platelets mismatched for these common antigens might not be cleared even if antibody against these antigens was present. 5 Indeed, these strategies proved to be of benefit in approximately 75% of alloimmunized recipients. Thus, clinicians cannot assume that the results of HLA-matched platelets will always be satisfactory and it is imperative that the results using different donor selection approaches be monitored closely in individual patients and used in future donor selection strategies.
There are several options for refractory patients for whom HLA-matched donors cannot be identified. One approach in bleeding patients is to infuse large amounts of pooled random donor platelets on the off chance that one of the many donors represented in the pool will be a match. In some patients, such large transfusions may also transiently absorb the antibody, allowing some subsequently transfused platelets to survive. 6 Because alloantibodies seem to be biologically different than autoantibodies, conventional approaches to the treatment of immune thrombocytopenic purpura such as high-dose corticosteroids, splenectomy, plasma exchange and in particular, high-dose intravenous IgG are ineffective. We treated alloimmunized patients who were refractory to random donor platelets and had HLA antibody, with high-dose intravenous IgG (0.4 g/kg/day × 5 days) and then rechallenged them with random donor platelet transfusions. In one study, 0/11 patients had improved increments from random donor or poorly matched single donor transfusions following the IgG, although 9/10 responded to HLA-identical transfusion. In another study of 15 patients, similar results were obtained. 7, 8 Given the cost of IgG, and the lack of benefit, its use in this setting cannot be justified.
Cryopreservation of platelets harvested during remission from patients with autologous retransfusion during episodes of subsequent thrombocytopenia, is another more anticipatory approach to management of alloimmunization. In many such patients refractory to random donor platelet transfusion and without histocompatible donors or siblings, multiple courses of intensive postremission consolidation chemotherapy have been administered using autologous platelets alone. Although there is some damage and platelet loss produced by freezing and thawing, overall, autologous frozen platelet transfusions produce increments about 60% of those achievable with fresh platelet preparations. 9 Lastly, crossmatching of donors and recipients using a variety of antiplatelet antibody assays can identify compatible donors and supplement donor selection by HLA typing. Many blood centers now do such crossmatches on the single donor apheresis products collected in their centers in order to select compatible units. Another approach is to crossmatch large numbers of random donor platelet concentrates, which are always available in blood centers. Compatible units are transfused and if the increments are satisfactory, then the original whole blood donors are identified and utilized for apheresis. In some instances, it is necessary to screen Ͼ100 units of platelet concentrate to find one or two donors who are compatible, illustrating the difficulties one may encounter in donor selection for strongly alloimmunized patients. 10 A number of studies have suggested that antigens presented by leukocytes rather than platelets are the primary immunogen. Leukocyte depletion of blood products by filtration and the experimental approach of ultraviolet B irradiation of the platelet product can decrease sensitization significantly. In the recently completed TRAP study of 600 AML patients, newly diagnosed patients were randomized to receive pooled random donor PC (control group), single donor filtered, random donor filtered PC and random donor UV-B irradiated PC.
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Most of these patients had prior exposure to HLA antigens via either pregnancy or transfusion. There was a statistically significant and virtually identical reduction in the rate of lymphocytotoxic antibody formation and a smaller, but significant decrease in the incidence of immune-mediated refractoriness in all of the experimental groups compared to the controls. The mean time to the development of antibodies was 2-3 weeks, when most patients no longer required frequent transfusions. Therefore, the clinical benefit was more manifest in postremission therapy when these patients can become difficult to manage. Importantly, single donor platelets were not superior to pooled random donor platelets, with both preparations producing similar post-transfusion increments and the same low incidence of transfusion reactions.
Recent randomized studies with megakaryocytic growth factors have failed to demonstrate significant reductions in platelet transfusion requirements or more rapid platelet count recovery in patients with AML receiving induction and consolidation chemotherapy. 12, 13 In normal subjects, there is a delay of about 1 week until rises in platelet counts occur after thrombopoietin administration and, since thrombopoietin was not begun until after the completion of chemotherapy, any effect of megakaryocyte stimulation would not be seen until the third or fourth week of treatment, thereby making it difficult to produce a clinically meaningful effect. In addition, levels of endogenous thrombopoietin vary inversely with the platelet count, and these patients may already be maximally stimulated endogenously with little added effect of even pharmacologic doses of exogenous thrombopoietin.
Recent randomized trials in patients with acute leukemia have demonstrated that there is no difference in outcome between patients transfused prophylactically at counts of either 10 000 or 20 000/l in the incidence of major bleeding, complete response rates, or overall survival. [14] [15] [16] It is unknown how many platelets are needed to maintain hemostasis and what level provides a safe buffer against acute events. Observational studies suggest that even lower transfusion 'triggers' are safe in patients with aplastic anemia, suggesting that the threshold may in fact be even lower. 17 Thus, it is likely that there will be further refinement of the need for platelet transfusions in clinically stable patients without bleeding in the future.
There has been a recent flurry of interest in the use of nonviable platelet substitutes in contrast to the traditional transfusion of intact platelets (reviewed by Alving et al. 18 ). Lyophilized and freeze dried platelets, as well as platelet membranes and even erythrocytes to which subendothelial binding proteins have been attached ('thromboerythrocytes') are under evaluation. The operative hypothesis with all of these products is that the substitute will bind to exposed subendothelium providing an adequate stimulus for the coagulation cascade and clot formation. The appeal of these approaches is the potential for a sterilized product with an essentially indefinite shelf life, providing a ready store of platelets at all times. In a sense, the pharmacy could replace the blood bank.
Testing these different products clinically to demonstrate hemostatic effectiveness is a complex task. Platelet transfusion products have traditionally been evaluated by their ability to produce platelet count increments in thrombocytopenic recipients. In contrast, proof of benefit from platelet substitutes will depend on demonstration of a hemostatic effect. It is, however, extremely difficult to objectively measure hemorrhage in thrombocytopenic patients; severe hemorrhage is rare and gastrointestinal and urinary tract hemorrhage, which are somewhat quantifiable, are even less common.
It might also turn out that platelet substitutes will be of benefit in only selected situations. For example, it is quite possible that the platelet substitutes will participate with the coagulation system only with the stimulation and participation of residual circulating platelets. Thus, there might be differences in efficacy in thrombocytopenic patients with somewhat higher counts vs those with very low counts of less than 5000/l. It is expected that these issues will be addressed in upcoming studies involving these products, but the first barrier will be to design a clinical trial in humans by which benefit can be determined objectively, remembering that an adequate and well-proved alternative, viable stored platelets, is currently readily available. Certainly the field would benefit from an in vitro model predictive of hemostatic capability in vivo, which at a minimum could help screen modifications of these platelet substitutes.
